Thursday, March 3, 2011
Briefs: DNDN Reports Earnings; EPCT's New Ceplene Data
DNDN: Dendreon announced earnings this week, as expected, and there were no surprises as it has been expected that the company will continue having problems meeting the high demand for Provenge until the manufacturing capacity increases, which should be the case later this year.
That said, Provenge sales increased from $20 to $24 million quarter-over-quarter, although losses also grew significantly, but again, that is mainly attributed to bringing the manufacturing plants on line.
Look for major growth in Provenge revenue towards the end of the year, and on the other side of the coin, keep an eye out for setbacks at the manufacturing plants that might delay them coming on line in the expected time frame.
Still a stellar stock story, and there's still plenty of room for growth.
Disclosure: No position.
EPCT: Epicept Corporation announced on Wednesday that a subgroup with statistically significant survival benefits was identified from data collected in the already completed Phase III trial for Ceplene in Acute Myeloid Leukemia (AML) administered with low-dose interleukin-2 (IL-2).
The subgroup data, according to Epicept's press release, will be used to design the upcoming Phase III trial that is required before the US FDA will review Ceplene for approval. If all goes according to plan, which is always questionable when dealing with the FDA, then the trial will commence during the second half of this year.
While approval in the United States is generally more of milestone for companies than European approvals, there's plenty of growth potential for Ceplene to be had in Europe over the short term to keep things interested as the path for US approval gets underway.
After having a few sub-par years and a significant delay in bringing Ceplene to market in Europe, Epicept looks to be a company on the rebound.
Disclosure: Long EPCT.